Pharmacogenomics in early-phase clinical development
T Burt, S Dhillon - Pharmacogenomics, 2013 - Taylor & Francis
Pharmacogenomics (PGx) offers the promise of utilizing genetic fingerprints to predict
individual responses to drugs in terms of safety, efficacy and pharmacokinetics. Early-phase …
individual responses to drugs in terms of safety, efficacy and pharmacokinetics. Early-phase …
Pharmacogenomics in early-phase clinical development
T Burt, S Dhillon - Pharmacogenomics, 2013 - go.gale.com
Background There are many interindividual differences in response to drug therapy, many
may not matter, but some do and may pertain to the interaction of drug with genetically …
may not matter, but some do and may pertain to the interaction of drug with genetically …
[HTML][HTML] Pharmacogenomics in early-phase clinical development
T Burt, S Dhillon - Pharmacogenomics, 2013 - ncbi.nlm.nih.gov
Pharmacogenomics (PGx) offers the promise of utilizing genetic fingerprints to predict
individual responses to drugs in terms of safety, efficacy and pharmacokinetics. Early-phase …
individual responses to drugs in terms of safety, efficacy and pharmacokinetics. Early-phase …
Pharmacogenomics in early-phase clinical development
T Burt, S Dhillon - Pharmacogenomics, 2013 - pubmed.ncbi.nlm.nih.gov
Pharmacogenomics (PGx) offers the promise of utilizing genetic fingerprints to predict
individual responses to drugs in terms of safety, efficacy and pharmacokinetics. Early-phase …
individual responses to drugs in terms of safety, efficacy and pharmacokinetics. Early-phase …
Pharmacogenomics in early-phase clinical development.
T Burt, S Dhillon - Pharmacogenomics, 2013 - europepmc.org
Pharmacogenomics (PGx) offers the promise of utilizing genetic fingerprints to predict
individual responses to drugs in terms of safety, efficacy and pharmacokinetics. Early-phase …
individual responses to drugs in terms of safety, efficacy and pharmacokinetics. Early-phase …
[PDF][PDF] Pharmacogenomics in early-phase clinical development
T Burt - Pharmacogenomics, 2013 - core.ac.uk
Pharmacogenomics (PGx) offers the promise of utilizing genetic fingerprints to predict
individual responses to drugs in terms of safety, efficacy and pharmacokinetics. Early-phase …
individual responses to drugs in terms of safety, efficacy and pharmacokinetics. Early-phase …
Pharmacogenomics in early-phase clinical development
T Burt, S Dhillon - Pharmacogenomics, 2013 - search.proquest.com
Pharmacogenomics (PGx) offers the promise of utilizing genetic fingerprints to predict
individual responses to drugs in terms of safety, efficacy and pharmacokinetics. Early-phase …
individual responses to drugs in terms of safety, efficacy and pharmacokinetics. Early-phase …
[PDF][PDF] Pharmacogenomics in early-phase clinical development
T Burt - Pharmacogenomics, 2013 - dukespace.lib.duke.edu
Pharmacogenomics (PGx) offers the promise of utilizing genetic fingerprints to predict
individual responses to drugs in terms of safety, efficacy and pharmacokinetics. Early-phase …
individual responses to drugs in terms of safety, efficacy and pharmacokinetics. Early-phase …
Pharmacogenomics in early-phase clinical development.
T Burt, S Dhillon - 2013 - dukespace.lib.duke.edu
Pharmacogenomics (PGx) offers the promise of utilizing genetic fingerprints to predict
individual responses to drugs in terms of safety, efficacy and pharmacokinetics. Early-phase …
individual responses to drugs in terms of safety, efficacy and pharmacokinetics. Early-phase …